# REGENXBIO Inc. (RGNX) · Edgar & Edgarette company card

> Regenxbio (RGNX) grew revenue 105% in FY2025 to $170 million, operating margin -94.6% against a -15.8% median for biological products, (no diagnostic substances), equity 22.7% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1590877 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/RGNX) · [JSON](https://www.pops4.com/boards/company/RGNX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $170M |
| Revenue growth, 1 year | 104.5% |
| Revenue growth per year | -22.4% |
| Operating margin | -94.6% (prior year -280.0%) |
| Net margin | -113.8% |
| Operating cash flow | −$124M |
| Capital spending | $2M |
| Free cash flow | −$126M |
| Cash | $34M |
| Long-term debt | — |
| Total assets | $453M |
| Total equity | $103M |
| Equity ÷ assets | 22.7% |
| Return on equity | -188.7% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -7.82 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -94.6% in FY2025; revenue is hard to predict: its 80% range is ±49%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $170.4M (FY2025). Experience: revenue up 104.5% on the year, down 22.4% a year over 4 years; operating margin -94.6%, up from -280.0%. Soundness: equity 22.7% of assets, return on equity -188.7%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $156.7M and $461.0M next year (method v4.1: its own 3-year record of growth weighed at 40% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $119.3M to $612.4M. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -94.6% against a -15.8% median; growth 104.5% against 21.4%.

Range logged 2026-09-24, receipt 2ff7965e6256b823, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-10-16 ([filing](https://www.sec.gov/Archives/edgar/data/1590877/000119312526423376/0001193125-26-423376-index.htm))

## Recent filings

- 10-Q · filed 2026-11-05 · [filing](https://www.sec.gov/Archives/edgar/data/1590877/000119312526448581/0001193125-26-448581-index.htm)
- 8-K · filed 2026-11-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1590877/000119312526448559/0001193125-26-448559-index.htm)
- 8-K · filed 2026-10-16 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1590877/000119312526423376/0001193125-26-423376-index.htm)
- 8-K · filed 2026-09-23 · 1.01 Entry into a Material Definitive Agreement · [filing](https://www.sec.gov/Archives/edgar/data/1590877/000119312526399377/0001193125-26-399377-index.htm)
- 8-K · filed 2026-08-25 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1590877/000119312526365287/0001193125-26-365287-index.htm)
- 8-K · filed 2026-08-24 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1590877/000119312526363786/0001193125-26-363786-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001590877.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1590877

## Cite

POPS4, Edgar & Edgarette: REGENXBIO Inc. (RGNX) company card, from the company's own SEC filings, accessed 2026-11-08, https://www.pops4.com/boards/company/RGNX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.